Evaluation of antitumor potential of an anti-glypican-1 monoclonal antibody in preclinical lung cancer models reveals a distinct mechanism of action.
Minghua LiYanhong WangXiaoyang LinHaiqiang YangXiaolin ZhangYun BaiXiankun LiLulu ZhangFeng ChengChuan-Hai CaoQingyu ZhouPublished in: Exploration of targeted anti-tumor therapy (2024)
The relatively potent cytotoxicity of anti-GPC1 mAb in lung fibroblasts and its potential inhibitory effect on the paracrine FGFR signal transduction warrant further studies on the combined use of this mAb with targeted therapeutics to improve therapeutic outcomes in lung cancer.